胸腺肽α1、α干扰素和拉米夫定联合治疗HBV慢性携带者的临床研究

Clinical study of the efficacy of combination therapy of lamivudine, Interferon - aplpha and Thymosin - alphal in chronic hepatitis B virus carrier.

观察胸腺肽α1、α干扰素和拉米夫定联合治疗HBV慢性携带者的临床疗效。选择HBsAg、HBeAg、抗- HBc、HBV DNA阳性,肝功能正常的HBV慢性感染者72例,分为联合治疗组42例:拉米夫定0．1／d,口服,疗程52 周;胸腺肽α1 1．6mg／次,皮下注射,2次／周,连续26周;α干扰素500万单位／日,肌注,疗程26周。单用拉米夫定组 30例:剂量、疗程同联合治疗组。联合治疗组HBV DNA阴转率在26周时76．2％,52周时81．0%,拉米夫定组为 50．0％和66．7％。联合治疗组HBeAg阴转率26周时33．3％,52周时38．1％,拉米夫定组为10％和13．3％。HBeAg 血清转换率两组无统计学差异。联合治疗对HBV DNA和HBeAg的抑制作用显著优于单用药。

To evaluate the clinical efficacy of combination therapy of lamivudine, interferon- alpha and thymosin- alphal in chronic hepatitis B virus（HBV） carriers. Seventy- two chronic HBV carriers have been divided into two groups. Group one had 42 cases treated with combination of lamivudine, interferon - alpha and thymosin - alphal. Group two had 30 cases treated with lamivudine alone. All of the patients had serum positive marks of HBsAg, HBeAg and anti - HBc assayed by ELISA and of HBV DNA tested by PCR. The negative rate of serum HBV DNA in group one was 76.2% and 81.0% at the 26 weeks and 52 weeks respectively after treatment, but they were 50.0% and 66.7% in group two. The negative rate of serum HBeAg in group one was 33.3% and 38.1% at the 26 weeks and 52 weeks respectively after treatment, but they were 10% and 13.3% in group two. The conversion rate of HBeAg/HBeAb had no significant difference. Combination therapy can enhance the inhibition effect of HBV DNA and HBeAg in chronic HBV carriers.